NRSN Stock Analysis: Buy, Sell, or Hold?
NRSN - NeuroSense Therapeutics Ltd. Ordinary Shares
$0.81
0.06 (7.78%)
▲
5d:
+17.23%
30d:
+10.66%
90d:
-11.1%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: Jun 22, 2026
Get Alerted When NRSN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NRSN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NRSN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NRSN is currently trading at $0.81, which is considered extended relative to its 30-day fair value range of $0.71 to $0.77.
Technical Outlook: Technically, NRSN is in a downtrend. The price is approaching resistance at $0.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.8% recently.
Market Sentiment: NRSN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.38 (+935.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NRSN is in a downtrend. The price is approaching resistance at $0.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.8% recently.
Market Sentiment: NRSN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.38 (+935.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.71 -
$0.77
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+5.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.8%)
- BULLISH: Trading 935.4% below Wall St target ($8.38)
Trading Range Analysis
30-Day Trading Range
$0.71 -
$0.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.82
Current Trend
Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.60
Wall Street Target
$8.38
(+935.4%)
Share & Embed Analysis
Last updated: April 29, 2026 4:13 AM ET
Data refreshes hourly during market hours. Next update: 5:13 AM
Data refreshes hourly during market hours. Next update: 5:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRSN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$99 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
14 analysts |
$57 | 59 HOLD |
